FIELD: biotechnology.
SUBSTANCE: invention relates to a combination of antibodies for inducing immune tolerance to a cell obtained from an individual, containing an anti-CD86 antibody and an anti-CD80 antibody. Also disclosed is a nucleic acid molecule coding an anti-CD80 antibody or a variant thereof, a nucleic acid molecule coding an anti-CD86 antibody or a variant thereof, as well as a vector and a cell containing them. Invention also relates to a method of producing a cell involving the use of said combination.
EFFECT: invention is effective for induction of immune tolerance to a cell obtained in an individual.
9 cl, 9 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
| ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
| ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
| ANTIBODY AGAINST HUMAN FN14 | 2019 |
|
RU2787044C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
| CHO-SE-9/4 CELL STRAIN, PRODUCER OF CHIMERIC HUMAN ERYTHROPOIETIN ANTIBODY AND CHIMERIC ANTIBODY PRODUCED BY SAID STRAIN | 2019 |
|
RU2717038C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| UNIVERSAL ANTIBODY-MEDIATED BIOSENSOR | 2016 |
|
RU2746486C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
